The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy

J. R. Hutson; J. N. Matlow; M. E. Moretti; G. Koren

doi:https://doi.org/10.3109/01443615.2012.716106

The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy

J. R. Hutson, J. N. Matlow, M. E. Moretti, G. Koren

Research output: Contribution to journal › Review article › peer-review

Abstract

Maintaining remission of inflammatory bowel disease (IBD) during pregnancy is critical for positive pregnancy outcomes. Conflicting data exist regarding the association between thiopurine use for IBD treatment in pregnancy and adverse pregnancy outcomes and this meta-analysis aims to clarify this association. A meta-analysis was performed of all original human studies reporting outcomes in pregnancy in patients receiving thiopurines. Nine studies satisfied the inclusion criteria and a total of 494 patients with IBD and 2,782 IBD controls were reported. When compared with healthy women, those receiving thiopurines had an increased risk for congenital malformations (RR 1.45; 95% CI 1.071.96; p = 0.02); however, when compared with IBD controls, there was no increased risk (RR 1.37; 95% CI 0.922.05; p = 0.1). These data provide support for thiopurines having a minimal risk, if any, to the fetus.

Original language	English
Pages (from-to)	1-8
Number of pages	8
Journal	Journal of Obstetrics and Gynaecology
Volume	33
Issue number	1
DOIs	https://doi.org/10.3109/01443615.2012.716106
State	Published - Jan 2013
Externally published	Yes

Keywords

6-mercaptopurine
Azathioprine
Meta-analysis
Pregnancy

All Science Journal Classification (ASJC) codes

Obstetrics and Gynaecology

Access to Document

https://doi.org/10.3109/01443615.2012.716106

Cite this

@article{410ee7547efb4c92aa6b85fd979efa59,

title = "The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy",

abstract = "Maintaining remission of inflammatory bowel disease (IBD) during pregnancy is critical for positive pregnancy outcomes. Conflicting data exist regarding the association between thiopurine use for IBD treatment in pregnancy and adverse pregnancy outcomes and this meta-analysis aims to clarify this association. A meta-analysis was performed of all original human studies reporting outcomes in pregnancy in patients receiving thiopurines. Nine studies satisfied the inclusion criteria and a total of 494 patients with IBD and 2,782 IBD controls were reported. When compared with healthy women, those receiving thiopurines had an increased risk for congenital malformations (RR 1.45; 95% CI 1.071.96; p = 0.02); however, when compared with IBD controls, there was no increased risk (RR 1.37; 95% CI 0.922.05; p = 0.1). These data provide support for thiopurines having a minimal risk, if any, to the fetus.",

keywords = "6-mercaptopurine, Azathioprine, Meta-analysis, Pregnancy",

author = "Hutson, {J. R.} and Matlow, {J. N.} and Moretti, {M. E.} and G. Koren",

note = "Funding Information: This study is supported by a grant from the Canadian Institutes for Health Research (CIHR). JRH is supported by a CIHR Vanier Canada Graduate Scholarship. GK is the holder of the Ivey Chair in Molecular Toxicology, The Department of Medicine, University of Western Ontario and the Research Leadership for Better Pharmacotherapy During Pregnancy and Breastfeeding, The Hospital for Sick Children.",

year = "2013",

month = jan,

doi = "https://doi.org/10.3109/01443615.2012.716106",

language = "الإنجليزيّة",

volume = "33",

pages = "1--8",

journal = "Journal of Obstetrics and Gynaecology",

issn = "0144-3615",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy

AU - Hutson, J. R.

AU - Matlow, J. N.

AU - Moretti, M. E.

AU - Koren, G.

N1 - Funding Information: This study is supported by a grant from the Canadian Institutes for Health Research (CIHR). JRH is supported by a CIHR Vanier Canada Graduate Scholarship. GK is the holder of the Ivey Chair in Molecular Toxicology, The Department of Medicine, University of Western Ontario and the Research Leadership for Better Pharmacotherapy During Pregnancy and Breastfeeding, The Hospital for Sick Children.

PY - 2013/1

Y1 - 2013/1

N2 - Maintaining remission of inflammatory bowel disease (IBD) during pregnancy is critical for positive pregnancy outcomes. Conflicting data exist regarding the association between thiopurine use for IBD treatment in pregnancy and adverse pregnancy outcomes and this meta-analysis aims to clarify this association. A meta-analysis was performed of all original human studies reporting outcomes in pregnancy in patients receiving thiopurines. Nine studies satisfied the inclusion criteria and a total of 494 patients with IBD and 2,782 IBD controls were reported. When compared with healthy women, those receiving thiopurines had an increased risk for congenital malformations (RR 1.45; 95% CI 1.071.96; p = 0.02); however, when compared with IBD controls, there was no increased risk (RR 1.37; 95% CI 0.922.05; p = 0.1). These data provide support for thiopurines having a minimal risk, if any, to the fetus.

AB - Maintaining remission of inflammatory bowel disease (IBD) during pregnancy is critical for positive pregnancy outcomes. Conflicting data exist regarding the association between thiopurine use for IBD treatment in pregnancy and adverse pregnancy outcomes and this meta-analysis aims to clarify this association. A meta-analysis was performed of all original human studies reporting outcomes in pregnancy in patients receiving thiopurines. Nine studies satisfied the inclusion criteria and a total of 494 patients with IBD and 2,782 IBD controls were reported. When compared with healthy women, those receiving thiopurines had an increased risk for congenital malformations (RR 1.45; 95% CI 1.071.96; p = 0.02); however, when compared with IBD controls, there was no increased risk (RR 1.37; 95% CI 0.922.05; p = 0.1). These data provide support for thiopurines having a minimal risk, if any, to the fetus.

KW - 6-mercaptopurine

KW - Azathioprine

KW - Meta-analysis

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84871496472&partnerID=8YFLogxK

U2 - https://doi.org/10.3109/01443615.2012.716106

DO - https://doi.org/10.3109/01443615.2012.716106

M3 - مقالة مرجعية

C2 - 23259868

SN - 0144-3615

VL - 33

SP - 1

EP - 8

JO - Journal of Obstetrics and Gynaecology

JF - Journal of Obstetrics and Gynaecology

IS - 1

ER -

The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy

Abstract

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this